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ABSTRACT 
 
Aggregation of specific proteins in the 
brains of patients with chronic mental illness 
as a result of disruptions in proteostasis is an 
emerging theme in the study of schizophrenia 
in particular. Proteins including DISC1 
(Disrupted in Schizophrenia 1) and 
dysbindin-1B are found in insoluble 
accumulations within brain homogenates 
from such patients. We recently identified 
TRIOBP-1 (Trio-Binding Protein 1, also 
known as Tara) to be another such protein 
through an epitope discovery and proteomics 
approach, comparing post mortem brain 
material from schizophrenia patients and 
control individuals. We hypothesized that this 
was likely to occur as a result of a specific 
subcellular process, and that it therefore 
should be possible to identify a region of the 
TRIOBP-1 protein which is essential for its 
aggregation to occur. 
 Here, we probe the domain 
organization of TRIOBP-1, finding it to 
possess two distinct coiled coil domains: the 
central and C-terminal domains. The central 
domain inhibits the de-polymerization of F-
actin and is also responsible for 
oligomerization of TRIOBP-1 and, along with 
an N-terminal Pleckstrin homology domain, 
affects neurite outgrowth.  
In neuroblastoma cells, it was found 
that the aggregation propensity of TRIOBP-1 
arises from its central domain, with a short 
“linker” region, narrowed to within amino 
acids 324-348, between its first two coiled-coils 
being essential for the formation of TRIOBP-
1 aggregates. TRIOBP-1 aggregation 
therefore appears to occur through one or 
more specific cellular mechanisms, which 
therefore have the potential to be of 
physiological relevance for the biological 
process underlying the development of 
chronic mental illness. 
______________________________________ 
 
The TRIOBP (Trio-Binding Protein) 
gene encodes for two distinct proteins (1,2), both 
of which are implicated in the modulation of 
actin, although the exact mechanisms by which 
they do this remain unclear (3,4). Of these 
TRIOBP-4, encoded by the 5’ end of the gene, is 
a largely disordered protein (5), expressed 
principally in the inner ear and implicated in 
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deafness (1,2,4), while the 3’-encoded TRIOBP-
1 protein is predicted to be folded (3) and is 
more ubiquitously expressed (1,2). The 
TRIOBP-1 protein is also known as Tara (Trio-
Associated Repeat on Actin). Longer proteins 
containing the reading frames of both TRIOBP-1 
and TRIOBP-4 also exist (1,2) but are less well 
characterized. 
Recently, we performed an antibody-
based screen for proteins which specifically form 
insoluble aggregates in the brains of patients 
with schizophrenia (6). This was based on the 
theory that disrupted protein homeostasis in post-
mitotic neurons is likely to characterize subtypes 
of chronic mental illness (7). In this manner, an 
antibody against TRIOBP-1 was found to show 
specificity for the pooled purified insoluble 
protein fractions of post mortem brain samples 
from schizophrenia patients, compared to an 
equivalent preparation prepared from brain 
samples of control individuals (8). Further 
analysis determined the TRIOBP-1 protein, but 
not TRIOBP-4, to readily form insoluble 
aggregates when expressed in cell culture 
systems or primary neurons, implicating 
aggregation of TRIOBP-1 in mental health (8). 
The specific roles of TRIOBP-1 in the 
brain are not well studied, however more 
generally it is known to be a critical promoter of 
actin polymerization, binding directly to 
polymerized fibres of F-actin (3,9). It is also 
involved in chromosome segregation during 
mitosis (10), as well as in cell migration. The 
latter occurs through its interaction with Nuclear 
Distribution Element-Like 1 (NDEL1) (11), a 
protein of significant importance in 
neurodevelopment which has been implicated in 
schizophrenia (12). Small, but statistically 
significant, increases in TRIOBP transcript 
expression have also been detected in post-
mortem brain tissue of schizophrenia patients 
from two independent samples (13). 
The misassembly of TRIOBP-1 protein 
into insoluble aggregates in mental illness could 
arise either because the protein is naturally 
“sticky”, with a tendency to self-interact in a 
non-specific manner, or as the result of a specific 
physiological mechanism. Such mechanisms 
could include, for example, the addition or 
removal of a protein-binding partner, a post-
translational modification, interaction with a 
small molecule or an error during protein 
folding. We hypothesized that, were a specific 
mechanism involved, it should be possible to 
isolate individual regions of the protein which 
were involved in this process (either small motifs 
or entire folded domains) and which are 
therefore required for aggregation of TRIOBP-1. 
In this manuscript, we therefore 
investigate the domain structure of TRIOBP-1 
and establish that such an aggregation-critical 
region exists, which can be narrowed down to a 
stretch of just 25 amino acids (aa), strongly 
supporting the idea that a specific mechanism 
exists by which TRIOBP-1 forms insoluble 
aggregates. 
 
Results 
 
Predicted coiled-coil structure of TRIOBP-1 and 
inclusion of its N-terminus – Previous 
predictions have suggested that  TRIOBP-1 
(RefSeq accession number NP_008963.3) 
contains a Pleckstrin homology (PH) domain 
near its N-terminus, while the majority of its C-
terminal half forms α-helices, most likely in the 
form of coiled-coil domains (3). The potential 
coiled-coil composition of the C-terminal half of 
TRIOBP-1 was investigated theoretically using 
PSIPRED (14,15) and COILS (16) (Fig. 
1A,B,C), with reference also to Paircoil2 (17). In 
this manner, we predicted the existence of six 
distinct putative coiled-coils (Fig. 1D) in human 
TRIOBP-1, which will be referred to as CC1-
CC6. Of these, CC3, CC4 and CC5 are 
comparatively long stretches (running from 
approximately aa 395-465, aa 473-550 and aa 
566-617 respectively), while CC1, CC2 and CC6 
are shorter (aa 303-322, aa 352-372 and aa 623-
642 respectively). 
Note, that in this manuscript, the amino 
acids of human TRIOBP-1 are numbered based 
on a 652 aa long reading frame. This is 59 aa 
longer than the 593 aa reading frame considered 
in many other publications (3,10,11,18-20) as a 
result of the existence of two putative Kozak 
sequences and methionine residues at the 5’ end 
of the TRIOBP-1 transcript. Amino acid numbers 
quoted here for the 652 aa protein can therefore 
be converted to directly to positions in the 593 aa 
protein considered elsewhere by subtracting 59. 
We chose to include these additional 59 aa N-
terminal region in the amino acid numbered as it 
is relatively well conserved and maintains its 
reading frame throughout mammalian species 
(Fig. 2A). Nevertheless, TRIOBP-1 species 
containing this region appear to represent a 
minority in cells (Fig. 2B) and therefore arise 
either from a less common translation event, or 
else they represent the approximate position of a 
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“pro” domain which is normally cleaved off in 
the cell. This 59 aa N-terminal region is rich in 
both prolines and positively charged residues and 
localizes to both the cytoplasm and nucleus when 
expressed in neuroblastoma cells (Fig. 2C). 
 
The domain structure of TRIOBP-1 as 
determined by solubility and stability of 
recombinant protein fragments – In order to 
determine which regions have the potential to 
exist as distinct folded domains in vivo, different 
fragments of TRIOBP-1 were expressed as 
recombinant proteins. This was based on the 
premise that compactly folded protein domains 
are more likely to form soluble recombinant 
proteins, with distinct oligomeric states, both in 
bacteria and in vitro. In contrast, constructs 
encoding only part of such a region would 
instead be more likely to either degrade or form 
insoluble aggregates. In support of this idea, we 
began by investigating the strongly predicted PH 
domain at the N-terminus of TRIOBP-1. 
Expression of the whole PH domain (aa 60-189) 
led to a soluble recombinant protein which stably 
formed a dimer (apparent molecular weight, 
MW, ≈30 kDa, compared to a predicted MW of 
17.3 kDa,) as analyzed by size exclusion 
chromatography (SEC, Fig. 3A). Circular 
dichroism (CD) analysis confirmed this protein 
to be structured, with a high β-sheet content, 
approximately 50% as predicted in DichroWeb  
using the CDSSTR method and SMP180 dataset 
(21-25), which is consistent with the typical 
structure of PH domains (Fig. 3B). In contrast, 
expression of a shorter construct lacking the N-
terminal-most predicted β-strand of the PH 
domain (aa 93-189) led to an unstable 
recombinant protein. Specifically, the protein 
formed a high oligomeric state void volume 
species, excepting for a portion of the protein 
which instead broke down to yield a smaller 
soluble product (Fig. 3C). 
Based on the principle that solubility and 
stability of a recombinant protein fragment in 
vitro can indicate the presence of distinct and 
complete folded domains in vivo, as exemplified 
here by the PH domain, the structure of the C-
terminal half of TRIOBP-1 was investigated. 
When this whole coiled-coil region (aa 281-652) 
was expressed, it broke down within the bacteria 
into a number of discrete species (Fig. 4A & 4B), 
suggesting that the coiled coils region consists of 
at least two distinctly folded domains. Based on 
the sizes of the fragments detected with 
antibodies raised against different regions of the 
coiled coil region, a break between CC4 and 
CC5 was predicted. In agreement with this, 
expression of the extreme two C-terminal coiled 
coils of TRIOBP-1 (CC5 and CC6, aa 556-652) 
led to a single stable monomeric protein (Fig. 
4C, observed MW ≈20 kDa, predicted MW: 14 
kDa, discrepancy likely arising from coiled-coil 
protein forming an elongated structure), which 
has a predominantly α-helical structure as 
determined by CD (Fig. 4D). In contrast, 
inclusion of CC4 in the construct (CC4-CC6, aa 
467-652) led to an unstable protein which broke 
down prior to purification (Fig. 4E). Together 
this implies that CC5-6 constitute a distinctly 
folded structure which we will refer to as the “C-
terminal domain”.  
Expression of CC1-CC4 instead led to a 
predominant multimeric species with an apparent 
MW of approximately 200kDa (Fig. 5A, aa 281-
555, predicted MW for a monomer: 34.2 kDa), 
suggestive of a hexamer. CD demonstrated it to 
be principally α-helical (Fig. 5B). This multimer 
was prone to precipitation at high concentrations, 
and there was some evidence of degradation of 
the protein (80-100ml in Fig. 5A, also visible in 
Fig. 6E), suggesting that this protein fragment 
was largely, but not completely, stable in vitro.  
A further truncated recombinant protein 
containing CC1-CC3 was highly stable even at 
concentrations of over 10 mg/ml, and existed as 
seemingly the same single oligomeric species as 
the CC1-CC4 protein (Fig.5C, aa 281-466, 
apparent MW: ≈160 kDa, predicted MW of a 
monomer: 24 kDa, again suggestive of a 
hexamer) and also had a high helical content 
(Fig. 5D). While these in vitro analyses may not 
necessarily completely reflect the situation in 
vivo, they strongly suggest that CC1-CC3 of 
TRIOBP-1 forms a folded “central domain”, 
potentially also including CC4, but distinct from 
the C-terminal domain of CC5 & CC6. 
When only the short CC1 & CC2 coiled 
regions were expressed, the ensuing protein 
appeared to be either a trimer or an extended 
dimer (Fig. 5E, aa 281-382, apparent MW: ≈40 
kDa, predicted MW for a monomer: 14.1 kDa) 
and to be reasonably stable, although less so than 
the CC1-CC3 protein and with a lower α-helix 
content (Fig. 5F). Expression of CC2 & CC3 led 
to a similarly stable trimeric protein (Fig. 5G, aa 
349-466, apparent MW: ≈55 kDa, predicted MW 
for a monomer: 16.2 kDa), which consisted 
almost entirely of α-helical structure (Fig 5H).  
To further investigate the oligomeric 
state of the central domain, these constructs were 
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investigated using analytical ultracentrifugation 
(AUC). AUC sedimentation velocity 
experiments showed the CC1-CC2 fragment to 
exist predominantly as a species with an 
estimated MW of 26.0 kDa (Perrin factor, s20,w = 
1.15 S, Fig. 6A,B), consistent with a dimer. It 
had a frictional ratio of 1.61, indicative of an 
extended conformation. Under the same 
experimental circumstances, most of the CC2-
CC3 construct adopted an oligomeric state 
consistent with a monomer, only 1.8% of the 
protein remained as a species matching the one 
seen by SEC, with a predicted MW of 49.4 kDa 
(s20,w = 3.46 S, Fig. 6A,C). This region was even 
more elongated that CC1-CC2, with a frictional 
ratio of 1.82, consistent with it consisting of 
extended coiled coil structure. When CC1-CC3 
was similarly examined, it did not maintain the 
same high order oligomeric state seen by SEC, 
with an apparent trimer being the largest species 
(observed MW of 76.3 kDa, compared to a 
theoretical MW of 23.9 kDa, Fig. 6A,D). This 
was also highly elongated (frictional ratio: 1.63). 
It therefore appears that the central domain 
trimerizes through interactions of CC2-CC3, but 
is also capable of forming higher order 
oligomers, most likely hexamers, through the 
additional dimer-forming capacity contained 
within CC1-CC2. 
The nature of all soluble TRIOBP-1 
constructs used here could be confirmed by 
Western blot using anti-TRIOBP antibodies 
raised against different sections of the protein 
(figure 6E). 
 
Functional analysis of the individual 
domains of TRIOBP-1 – Following identification 
of two distinct coiled-coil domains of TRIOBP-
1, in addition to the previously predicted PH 
domain, initial experiments were carried out to 
investigate their functions in the cell, the results 
of which are summarized in table 1.  
The canonical role of TRIOBP-1 is as a 
modulator of actin polymerization, leading to 
increased fibular F-actin compared to globular 
G-actin (3), although the mechanism by which it 
does this so far has been unknown. The ability of 
the individual domains of TRIOBP-1 on actin 
polymerization was therefore investigated. NLF 
neuroblastoma cells were transfected with 
constructs encoding the PH domain, central 
domain (CC1-4) C-terminal domain (CC5-6) of 
TRIOBP-1 and lysed in a buffer which stabilizes 
polymerized F-actin (26). The ensuing lysates 
were then separated by ultracentrifugation into 
an F-actin containing pellet and a G-actin 
containing supernatant (Fig. 7A). The 
supernatant was incubated under conditions 
which promote polymerization, before being 
separated once again by ultra-centrifugation into 
F- and G-actin containing fractions, in order to 
determine how much of the G-actin had re-
polymerized in the presence of each TRIOBP-1 
construct. Similarly, the original F-actin 
containing pellet was resuspended and 
equilibrated in conditions which favor de-
polymerization (27) and then separated by 
ultracentrifugation to determine what proportion 
of the polymeric F-actin had broken down into 
monomeric G-actin in the presence of each 
TRIOBP-1 construct (Fig. 7A). 
The central (CC1-CC4) and C-terminal 
(CC5-CC6) domains of TRIOBP-1 were found 
to segregate with both F- and G-actin in the 
assay, while the PH domain was found 
exclusively in soluble fractions, implying that 
both coiled coil domains, but not the PH domain, 
can interact with F-actin (Fig. 7B). As would 
therefore be expected, the presence of the PH 
domain had no effect on the dynamics of actin in 
this assay, when compared to mock transfected 
control cells (Fig. 7B,C,D). The central domain 
had no effect on the polymerization of G-actin 
(Fig. 7B,D), but did cause an almost 3-fold 
reduction in the amount of F-actin which de-
polymerized during the experimental time period 
(Fig. 7B,C). Expression of the C-terminal region 
was at a lower level than of the other two 
constructs, but nevertheless showed putative 
effects in limiting actin de-polymerization to the 
central domain (Fig. 7B,C), and in causing an 
increase in polymerization of G-actin (Fig. 
7B,D), although neither of these remained 
significant after correction for multiple testing. 
We therefore demonstrate for the first time that 
the central domain, and potentially the C-
terminal domain, but not the PH domain, is 
individually capable of interacting with F-actin 
and protecting it against de-polymerization, at 
least under these experimental conditions. 
The exact role of TRIOBP-1 in neurons 
remains obscure, however over-expression of 
full length TRIOBP isoforms has been shown to 
influence neurite outgrowth (8). To determine 
which domain(s) could be involved in this 
process, Neuroscreen-1 cells were transfected 
with constructs encoding these domains, or an 
empty vector control, and then induced to 
differentiate for 72 hours with nerve growth 
factor. The morphology of the ensuing 
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transfected cells was then examined by 
immunofluorescent microscopy and quantified in 
a blinded manner (Fig. 8A). Notably, expression 
of the PH domain led to a significant increase of 
approximately 30% in the number of neurites per 
cell (Fig. 8B, only neurites over 20 µm in length 
were considered), suggesting this domain to play 
an active role in neurite initiation. There was also 
an increase in the length of the longest neurite 
per cell following expression of the PH domain, 
although this did not survive correction for 
multiple testing (Fig 8C). In contrast, expression 
of the central domain led to an approximately 
30% decrease in neurite number relative to 
control cells (Fig 8B). The most likely 
explanation is that this is a dominant negative 
effect of expressing the actin-binding domain in 
isolation, and thus competing with endogenous 
TRIOBP-1. The C-terminal domain did not 
affect neurite outgrowth in this experiment. 
  
The aggregation propensity of TRIOBP-
1 is dependent on a 25 amino stretch between 
coiled coils 1 and 2 – In our previous paper, we 
found evidence that insoluble TRIOBP-1 may 
accumulate specifically in the brains of at least a 
subset of patients with schizophrenia (8). 
Furthermore, it was demonstrated that full length 
TRIOBP-1, or TRIOBP-1 lacking its PH domain, 
can be made to aggregate when over-expressed 
in neuroblastoma cells, thus providing a potential 
model for insoluble TRIOBP-1 in the brain (8). 
Similar aggregated accumulations of 
exogenously expressed TRIOBP-1 have also 
recently been reported by others (28). If the 
aggregation propensity of TRIOBP-1 arises as a 
result of a specific cellular mechanism, such as 
being modulated by a protein-protein interaction 
or post-translational modification, then it should 
be possible to identify a specific region of 
TRIOBP-1 which is critical for this aggregation 
event to occur. To investigate this, further 
constructs encoding fragments of TRIOBP-1 
were generated, this time fused to N-terminal 
Flag tags, and were expressed in human SH-
SY5Y neuroblastoma cells.  
Notably, while full length TRIOBP-1 
forms aggregates when over-expressed (Fig. 9A), 
the N-terminal region of TRIOBP-1 showed no 
such tendency, instead being found in the 
cytoplasm and at the periphery of the cell, where 
it co-localized with actin (aa 1-280, Fig. 9B). 
When the PH domain was expressed in isolation 
it showed a similar cell periphery/actin 
localization with no sign of aggregation, but was 
also found prominently in the nucleus (aa 60-
189, Fig. 9C). This was in agreement with our 
previous finding that deleting the PH domain of 
TRIOBP-1 did not ablate its aggregation 
propensity (8).  
In contrast, a construct encoding CC1-
CC6 of TRIOBP-1 was seen to form large 
accumulations in the cell (aa 281-652, Fig. 9D), 
as did a construct encoding just CC1-CC4, the 
central domain (281-555 Fig. 9E). Reinforcing 
that the aggregation propensity of TRIOBP-1 
arises from the central domain, the C-terminal 
domain alone formed a diffuse cytoplasmic 
pattern when the two coiled coil regions of this 
domain were expressed (CC5 & CC6, aa 556-
652, Fig. 9F), or when CC5 was expressed alone 
(aa 556-619, Fig. 9G). 
 In order to determine which section of 
the TRIOBP-1 central coiled domain was 
involved in aggregation, further truncation 
constructs were expressed in neuroblastoma 
cells. Notably, neither constructs containing only 
CC3-6, nor CC3-4 formed aggregates (aa 383-
652 and aa 383-555, Fig. 10A & 10B), implying 
that an aggregation-critical region or motif lies 
within the first two short coiled-coils. CC1 and 
CC2 alone were unstable and rapidly degraded 
when expressed in the cell, but could be 
stabilized by the addition of a CFP fusion protein 
(Fig. 10C). Alone, this region did not show clear 
aggregation, which was not a quenching effect of 
the CFP, as full length TRIOBP-1 fused to CFP 
formed clear aggregates (Fig. 10D). Instead, fine 
mapping of the aggregation critical region was 
performed by systematic removal of sections of 
the CC1-CC6 construct from the N-terminal end. 
Two constructs expressing CC2-CC6 were 
therefore generated, one incorporating a 25 aa 
stretch which lies between CC1 and CC2, and 
one lacking this short section. Dramatically, 
while the construct featuring this region formed 
aggregates (aa 324-652, Fig. 10E), the protein 
lacking it instead adopted a more natural 
cytoplasmic expression pattern (aa 349-652, Fig. 
10F).  
To determine whether these punctate 
structures really represented insoluble TRIOBP-
1 species, both constructs were expressed in cells 
which, after lysis, were subjected to a series of 
solubilization buffers and centrifugation steps in 
order to remove all but the most insoluble 
proteins. Upon examination by western blot, 
both the constructs encoding aa 324-652 and aa 
349-652 were seen to be present in cell lysates, 
but only 324-652 was retained in the insoluble 
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protein fraction (Fig. 11A), consistent with its 
representing an insoluble, aggregated TRIOBP-1 
species. This 25 aa “linker” region between CC1 
and CC2 therefore appears to be critical for its 
aggregation propensity. To further verify this, 
SH-SY5Y cells were transfected with five 
previously-employed TRIOBP-1 truncation 
constructs in a blinded manner and the number 
of TRIOBP aggregates per cell was quantified. 
The presence of this 25 aa region was shown to 
have a highly significant effect on the number of 
such aggregates in the cytoplasm (Fig. 11B), 
with three constructs containing the region 
having a mean of at least 1.3 aggregates per cell, 
compared to 0.1 or less for two constructs 
lacking this region. This therefore reinforces the 
idea that this subsection of the coiled central 
region is essential for aggregation. Amongst the 
cells displaying TRIOBP-1 aggregates (which 
for the purposes of this experiment were defined 
as any intense area of anti-Flag signal over 0.5 
µm in diameter in the cell body) there was 
variation in the size of TRIOBP-1 aggregate 
seen, but with no significant differences between 
the different TRIOBP-1 fragments used (Fig. 
11C). 
When tested by Western blot, there was 
some variation in the level of expression of 
proteins from these construct (Fig. 11D), likely 
representing variable levels of nonsense-
mediated decay, however there was no obvious 
correlation (positive or negative) between 
expression level and aggregation propensity.  
To further confirm the requirement of 
this region for aggregation, long TRIOBP-1 
constructs containing the entire coiled-coil 
region (aa 190-652, Fig. 11E) were confirmed to 
aggregate when expressed in SH-SY5Y, but not 
when this 25 aa region was deleted (aa 190-652 
Δ324-348, Fig. 11F). Note that these fragments 
could not be readily studied by SEC as, like the 
aa 281-652 construct (Fig 4A,B), they degraded 
into smaller stable fragments when purified from 
bacteria. The N-terminal region plus CC1-2 did 
not aggregate however (aa 1-382, Fig. 11G), 
demonstrating that while this 25 aa “linker” 
region is essential for aggregation to occur, it is 
not in itself sufficient to induce aggregation, 
requiring the presence of at least some other part 
of the central domain. The reason for this lack of 
aggregation is likely due to loss of a more C-
terminal section of TRIOBP-1, rather than a 
stabilizing effect of the PH domain, given that 
full length TRIOBP-1 aggregates (Fig. 9A, 10D) 
and previous experiments have shown that 
deletion of the PH domain has no effect on 
aggregation propensity (8). 
  
Discussion 
 
 Many chronic neurodegenerative 
conditions can be characterized by the presence 
of insoluble aggregates of specific proteins as 
evidence for aberrant proteostasis. The concept 
that aberrant proteostasis may also exist in 
psychiatric illness is an emerging one, with 
TRIOBP-1 being a potential example of such a 
protein, having been identified via a hypothesis-
free affinity proteomics approach using brain 
samples of patients with schizophrenia (8). 
 Here, we have demonstrated that a 
specific region of TRIOBP-1, bounded by aa 
324-348, is an absolute requirement for its 
aggregation, indicating that it is likely to occur 
through a specific physiological process, as 
opposed to the random aggregation of naturally 
“sticky” proteins. This was revealed through the 
expression of truncated TRIOBP-1 constructs in 
neuroblastoma cell lines. While these truncated 
forms of TRIOBP-1 are not believed to be 
expressed in vivo, their similarity in expression 
pattern to full length TRIOBP-1 suggests that 
they may nevertheless be a useful tool to study 
its protein aggregation. This 25 aa region lies 
between two short predicted coiled-coils, CC1 
and CC2 (Fig. 12A), which form a dimeric 
structure when expressed in isolation, but appear 
to be part of the larger hexameric central coiled 
coil domain. In our previous analyses (8), this 
portion of TRIOBP-1 was one of the less 
strongly predicted to contain an “aggregation 
motif”, with only the sequence around aa 230-
236 being predicted to have some aggregate-
forming propensity by the AGGRESCAN (29), 
FoldAmyloid (30) and ProA (31) servers. It was 
nor predicted as such by TANGO (32,33). In all 
instances, however, at least four sites elsewhere 
in the protein were more strongly predicted to be 
capable of inducing aggregation, thus this 
location for an aggregation-critical region was an 
unexpected result. The 25 aa region contains 
multiple proline residues (Fig. 12B), suggesting 
that it likely represents a turn between CC1 and 
CC2. It is also rich in charged amino acids, 
allowing for the possibility that TRIOBP-1 
aggregation is dependent on protein-protein 
interactions, of which several have previously 
been reported for TRIOBP-1 (3,18,19). That this 
region was not strongly predicted to have an 
innate aggregation propensity might further 
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implicate the involvement of additional proteins 
or other cellular factors in the aggregation 
process, with such factors instead interacting 
with TRIOBP-1 in a manner dependent on this 
25 aa region.  
The large size of the protein aggregates 
generated when TRIOBP-1 constructs 
incorporating this region were expressed, 
combined with the high variability in the sizes of 
this protein accumulations, are consistent with 
their consisting of unfolded or misfolded 
TRIOBP-1 species. The exact mechanism by 
which TRIOBP-1 aggregation occurs remains to 
be determined, but it is likely to be tied into its 
oligomeric state and/or its protein interaction 
partners. An E3 ubiquitin ligase, HECTD3 
(Homologous to E6-AP Carboxyl Terminus 
protein D3) has also been reported to be 
responsible for degradation of TRIOBP-1 (19), 
and it is therefore likely that disruption of this 
process could lead to aberrant TRIOBP-1 protein 
homeostasis, potentially including aggregation. 
 We have also more generally explored 
the domain organization of TRIOBP-1, which 
was strongly predicted to consist of an N-
terminal PH domain and a large C-terminal 
coiled-coil region. The predicted PH domain is 
now confirmed to be a distinctly folded region 
when expressed in vitro, and appears to be of 
functional relevance for the generation of 
neurites based on a neuron-like assays in cell 
culture. Furthermore, we have now found the 
coiled-coil region to consist of two distinct 
domains: the central domain consisting of CC1-
CC3, and potentially also of CC4, while the C-
terminal domain consists of CC5-CC6 (Fig. 
11A). The central region is responsible for the 
assembly of TRIOBP-1 oligomers, forming an 
oligomeric state comparable to that previously 
described for the full length protein (18), and 
containing the aggregation-critical region. CC4 
corresponds to the region of TRIOBP-1 recently 
identified to be required for interaction with 
NDEL1 and subsequent effects on cell migration 
(11) and also contains a known phosphorylation 
site of importance for mitotic progression (10). 
The central domain is also involved in neurite 
outgrowth, with its expression in isolation 
leading to a reduction in neurite number, 
possibly as a result of the truncation mutant 
having a dominant negative effect. 
 That expression of TRIOBP-1 leads to 
an increase in cellular polymerized F-actin is 
well established (3), and knockdown of 
TRIOBP-1 can be used as a tool to prevent F-
actin formation in the cell (9,34), however the 
mechanism by which it does this is unclear. Here 
we demonstrate that, at least when expressed in 
isolation, both the central and C-terminal 
domains can bind to F-actin, with the central 
domain limiting its de-polymerization. The C-
terminal domain also showed a trend towards the 
same effect.  These data suggest that the 
TRIOBP-1 protein promotes F-actin formation 
indirectly, by inhibiting its degradation into 
monomeric G-actin This is broadly in agreement 
with previous results showing that amino acids 
72-444 of TRIOBP-1 (adapted to the numbering 
system used here, and incorporating the PH 
domain plus approximately CC1-3) are sufficient 
to bind actin (3). That the central and C-terminal 
domains are each capable of modulating actin 
dynamics in isolation is analogous to the fact that 
both the TRIOBP-1 and TRIOBP-4 proteins 
modulate actin despite sharing no common 
amino acid sequence. It thus appears that longer 
isoforms of TRIOBP, such as TRIOBP-6, could 
contain at least three distinct actin-binding and 
modulating domains: the central and C-terminal 
regions of TRIOBP-1, plus the R1 motif of 
TRIOBP-4 (5). 
 To the best of our knowledge, four other 
proteins have so far been identified which may 
also form protein aggregates in mental illness. Of 
these, both DISC1 (Disrupted in Schizophrenia 
1) and dysbindin-1B are proteins encoded for by 
genetic risk factors for major mental illness, 
which were later found in insoluble protein 
fractions of subsets of patients with mental 
illness (35,36). CRMP1 (Collapsin Response 
Mediator Protein 1) was identified through a 
combination of genetics and our antibody-based 
proteomics approach (6), while NPAS3 
(Neuronal PAS domain protein 1) aggregation 
appears to occur in the presence of a point 
mutation which is found in a family with 
schizophrenia (37,38). In all these cases, like 
TRIOBP-1, over-expression of the protein in 
mammalian cells leads to the formation of 
protein aggregates (6,36,38), and in the case of 
DISC1 and dysbindin-1B this has also be seen in 
when transgenic human proteins are expressed in 
rodents (39-41). NPAS3 aggregation, like that of 
TRIOBP-1 appears to be dependent on a 
particular region of the protein, in this case 
narrowed to an approximately 100 aa long region 
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which including the aggregation-related point 
mutation (38). While such experiments have not 
been directly undertaken for the other proteins, 
early work on DISC1 did describe a central 
region of the protein as required for its 
subcellular localization to “puncta” (42) 
reminiscent of protein aggregates. Furthermore, a 
seemingly distinct region of the C-terminus has 
been shown to be responsible for the aggregation 
propensity of recombinant DISC1 proteins (43). 
TRIOBP-1 is therefore one of several 
proteins which appear to form aggregates in cell 
culture systems through specific, although not 
yet elucidated, cellular processes, and which are 
also implicated in forming insoluble complexes 
in the brain. If, as we would predict, these 
insoluble accumulations in the brain correspond 
in form and effect to the aggregated protein 
structures seen in cell culture systems, then 
further study of such aggregates would yield 
significant insight into the pathophysiological 
events underlying chronic mental illness. 
  
Experimental procedures 
 
Plasmid constructs - The human 
TRIOBP-1 652 aa open reading frame (RefSeq 
accession number NP_008963.3) was cloned 
from the cDNA of human SH-SY5Y 
neuroblastoma cells and then regions of the gene 
were subcloned. These reading frames were 
transferred into the pDONR/Zeo vector using BP 
clonase (plasmid and enzyme from Thermo 
Fischer Scientific, Darmstadt, Germany), except 
for the full-length protein which was cloned and 
ligated into the pENTR1A no ccDB vector (44) 
(E. Campeau, #17298, Addgene, Cambridge, 
MA, USA). These reading frames were then 
transferred using LR clonase II (Thermo Fischer 
Scientific) into one or more of the following 
destination vectors: pETG10A (A. Geerlof, 
EMBL, Heidelberg, Germany), pdcDNA-
FlagMyc (B. Janssens, #LMBP 4705, 
BCCM/LMBP Plasmid Collection, Zwijnaarde, 
Belgium) or pdECFP (45) (S. Wiemann, #LMBP 
4548, BCCM/LMBP Plasmid Collection). All 
constructs were confirmed by sequencing, and 
the expressed proteins confirmed by western 
blot. 
 
Recombinant protein expression and 
purification - Recombinant TRIOBP-1 fragments 
were expressed from pETG10A vectors in BL21 
Star (DE3) or Rosetta (DE3) pLysS E. coli 
(respectively from Thermo Fisher Scientific and 
Merck Millipore, Darmstadt, Germany) and 
induced with 0.2-1 mM IPTG under conditions 
optimized for each construct. Bacterial pellets 
were resuspended in 20 mM Tris pH 7.4, 500 
mM NaCl, 25 mM imidazole, 20 mM MgCl2 
containing protease inhibitors and DNaseI, and 
lysed by the addition of 1 mg/ml lysozyme and 
1% Triton X-100. Insoluble material was 
removed by centrifugation, and the soluble 
fraction incubated for 16 hours at 4⁰C with 
NTA-agarose resin (Qiagen, Hilden, Germany). 
Resin was then transferred to a gravity flow 
column and washed with 20 mM Tris pH 7.4, 
500mM NaCl, 25 mM imidazole. Protein was 
eluted by the addition of the same buffer 
containing 250 mM imidazole. Further 
purification was performed by SEC on a HiLoad 
16/600 Superdex 200pg column (GE Healthcare, 
Freiburg, Germany), pre-equilibrated with 20 
mM Tris pH 7.4, 150 mM NaCl. This was 
performed using an ÄKTA Pure system (GE 
Healthcare) which was kept cooled to 4-8 ⁰C at 
all times. Inferred molecular weights of protein 
peaks were calculated based on calibration with 
protein standards, and compared to theoretical 
molecular weights calculated using the ExPASy 
ProtParam tool (46). For CD and AUC analyses, 
proteins were transferred to 20 mM sodium 
phosphate pH 7.4, 150 mM sodium fluoride 
using a HiPrep 26/10 Desalting column (GE 
Healthcare). 
 
Circular dichroism – Protein samples 
were analyzed on a J-815 spectrometer (JASCO, 
Groß-Umstadt, Germany). Measurements were 
recorded at  = 260 nm to 185 nm, using a 1 nm 
resolution, 20 nm/min scan speed, 1 mm optical 
path length, an integration time of 0.5 s and a 
controlled temperature of 20 °C. An average 
reading was taken from ten spectra per 
experiment. A buffer only spectra was subtracted 
from these results, and the data was then 
transformed to units of mean residue ellipticity. 
Deconvolution of the data was performed in 
DichroWeb (21,22) using the CDSSTR method 
(23,24) and reference dataset SMP180 (25). 
 
Analytical Ultracentrifugation – 
Measurements were carried out using a Beckman 
Optima XL-A ultracentrifuge (Beckman-Coulter, 
Brea, CA, USA) equipped with an absorbance 
detector and an 8-hole rotor. For sedimentation 
velocity experiments, 400 μL samples were 
loaded into a 12 mm double-sector aluminum 
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cell. All samples were equilibrated to 20 °C and 
the centrifugation was performed at 20 °C at 
50,000 rpm. The absorbance readings of all 
samples were recorded at 285 nm with a radial 
resolution of 30 μm. Data were analyzed by 
Sedfit (version 15.01b) using the continuous c(s) 
distribution model. The partial specific volumes 
of the target proteins, buffer density and its 
viscosity were determined by Sednterp (version 
20130813BETA). All graphs were generated by 
GUSSI (version 1.2.1) and the reported s-values 
were normalized to s20,w -values. 
 
Western blot, gels and quantification - 
Acrylamide gels were run, transferred to 
nitrocellulose membranes and blocked according 
to standard protocols. Commercial antibodies 
were used against α-actin (#A2066, Sigma-
Aldrich, Munich, Germany, raised in rabbit)  the 
Flag tag (#F1804, Sigma-Aldrich, raised in 
mouse), the 6xHis tag (#27E8, Cell Signaling 
Technology, Danvers, MA, USA, raised in 
mouse), TRIOBP-1 (#SAB2102579, 
#HPA019769 and #HPA003747, Sigma-Aldrich, 
raised in rabbit against human TRIOBP-1 
recombinant protein fragments containing amino 
acids 144-193, 279-379 and 504-635 
respectively) and α-tubulin (#T9026, Sigma-
Aldrich, raised in rabbit). Antibody signal was 
visualized and quantified where necessary using 
IRDye secondary antibodies, an Odyssey Clx 
instrared imaging system and associated analysis 
software (LI-COR Biosciences, Bad Homburg, 
Germany). Total protein in acrylamide gels was 
visualized using InstantBlue (Expedeon, 
Swavesey, UK). 
 
Cell culture - The human neuroblastoma 
cell line SH-SY5Y (Leibniz Institute DMSZ, 
Braunshweig, Germany) was cultured in D-
MEM/F-12 containing 10% fetal calf serum, 1x 
MEM non-essential amino acids, penicillin and 
streptomycin. The human neuroblastoma cell 
line NLF (Children’s Hospital of Philadelphia, 
PA, USA) were grown in RPM1 1640 medium 
supplemented with 10% fetal calf serum, 2 mM 
L-glutamine, penicillin and streptomycin. The rat 
pheochromocytoma cell line Neuroscreen-1 
(Thermo Fischer Scientific) was grown in RPM1 
1640 medium supplemented with 10% horse 
serum, 5% fetal calf serum, 2 mM L-glutamine, 
penicillin and streptomycin.  Transfections were 
performed for 24 hours using Lipofectamine 
2000 according to manufacturers’ instructions. 
For neurite outgrowth experiments, Neuroscreen-
1 cells were given 50 ng/ml nerve growth factor 
for 72 hours, following transfection. All cell 
culture chemicals from Thermo Fischer 
Scientific. Cells expressing full length TRIOBP-
1 in a doxycycline-inducible manner were 
established using the Retro-X Tet-On Advanced 
Inducible Expression System (Clontech 
Laboratories, Mountain View, CA, USA). 
 
Immunocytochemistry - Cells were 
seeded on glass coverslips, fixed with PBS, 4% 
paraformaldehyde, permeabilized with PBS, 
0.5% Triton X-100 and blocked with PBS, 10% 
goat serum. Primary antibodies were applied and 
detected using Alex Fluor secondary antibodies 
(488 or 596 nm, Thermo Fischer Scientific). 
Actin was visualized using Acti-stain 488 
phalloidin (#PHDG1, Cytoskeleton, Inc., 
Denver, CO, USA) according to manufacturer’s 
instructions. This was also used to visualize total 
cell body and neurites in quantification 
experiments. Coverslips were mounted using 
ProLong Gold with DAPI (Thermo Fischer 
Scientific) and viewed on an LSM-510 confocal 
microscope (Carl Zeiss Microscopy, Göttingen, 
Germany) at room temperature. Images were 
taken using a Plan-Apochromat x100 objective, 
Immersol 518 immersion oil and ZEN 2 pro 
software (all from Carl Zeiss Microscopy). All 
images displayed are representative of at least 
three independent experiments.  
For the quantification experiments, 
plasmid DNA preparations were prepared and 
then coded, so that the researcher performing 
transfections and immunocytochemistry was 
blinded as to which TRIOBP-1 construct was 
used for each set of cells. Photographs were then 
taken of the first transfected cells identified by 
microscopy, and quantified measurements taken 
from these images (using ImageJ, version 
1.45s,(47)) prior to unblinding of the samples. 
Data was analyzed by one-way ANOVA, with 
Bonferroni correction for multiple testing. 
 
Insoluble protein fraction purification - 
Purification of the insoluble fractions of SHSY-
5Y cells was performed as described previously 
(8). Briefly, cells were lysed and washed with a 
series of buffers, variously containing 1% NP-
40, 0.2% Sarcosyl, DNaseI and/or 1.5 M NaCl, 
with centrifugation steps to remove all proteins 
solubilized by each buffer. The final pellet was 
then resuspended in loading buffer and probed 
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by western blot alongside samples of the 
original, unfractionated cell lysate. 
 
Actin polymerization assays – NLF 
neuroblastoma cells were transfected with 
constructs encoding regions of TRIOBP-1, or an 
empty control vector, and grown for 48 hours. 
Cells were then lysed at 37 °C with 50 mM 
PIPES pH 6.9, 50 mM NaCl, 5 mM MgCl2, 5 
mM EGTA, 5% glycerol, 0.1% NP-40, 0.1% 
Triton X-100, 1% Tween 20 plus protease 
inhibitor cocktail for 10 minutes with gentle 
shaking. Cell debris was removed by 
centrifuging at 350 × g for 10 mins. Cell lysate 
was then ultracentrifuged at 100,000 × g for 1 
hour at 37 °C and the G-actin containing 
supernatant removed. The supernatant was 
incubated for a further 60 mins at 37 °C and then 
ultracentrifuged again to test for additional 
polymerization of actin. Meanwhile, the F-actin 
containing pellet was resuspended in 5 mM Tris 
pH 8.0, 0.2 mM CaCl2, 0.2 mM ADP plus 
protease inhibitor cocktail. This was incubated 
for 4 hours at 4 °C to facilitate de-polymerization 
of actin, and then ultracentrifuged at 100,000 × g 
for 1 hour at 4 °C. Pellets from this second round 
of ultracentrifugation were resuspended in their 
respective buffers. Actin and TRIOBP-1 content 
was assayed by western blot. Experiment was 
repeated three times. 
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FIGURE 1: Predicting the coil structure of TRIOBP-1. (A) Prediction of coiled-coil forming 
propensity of the 652 amino acid TRIOBP-1 reading frame using the COILS server with a 21-amino 
acid sliding window. (B) Prediction of α-helix forming propensity using the PSIPRED server. (C) 
Prediction of β-sheet forming propensity using the PSIPRED server. (D) Proposed coiled-coil regions 
of TRIOBP-1 based on this data, shown in line with the graphs. The predicted Pleckstrin Homology, 
PH, domain is also displayed. 
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FIGURE 2; The extreme N-terminus of TRIOBP-1. (A) The putative initial 59 amino acids, aa, of 
TRIOBP-1, as present in multiple mammalian lineages. Notably, despite variation in amino acid 
sequence, and particularly in a poly-glycine stretch (green), all maintain the same reading frame. 
Positively charged residues are shown in red, negatively charged residues in blue and prolines in 
purple. Aligned using Clustal Omega (48) (http://www.ebi.ac.uk/Tools/msa/clustalo) and then 
manually curated. RefSeq accession number for the sequences shown are, in order displayed: 
NP_008963.3; XP_008065523.1; XP_009215517.1, XP_003126108.2; XP_006914811.1; 
XP_004410876.1; XP_007454108.1; XP_004279508.1; XP_004312195.1; XP_008849513.1; 
XP_005067025.1; XP_005067025.1; NP_001019887.1; XP_006242072.1; XP_005354277.1; 
XP_006979187.1; XP_005322324.1. (B) SH-SY5Y cells inducibly expressing the 652 aa species of 
TRIOBP-1, with and without induction of expression. The endogenous TRIOBP-1 species is seen to 
be of a slightly lower molecular weight than the 652 aa over-expressed protein, although a small 
amount of endogenous protein of this size is present, consistent with only a small portion of 
endogenous TRIOBP-1 protein expressing or maintaining the extreme N-terminus. (C) Expression of 
the N-terminal 59 aa of TRIOBP-1 alone in SH-SY5Y cells with a Flag tag.  
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FIGURE 3: Completeness of the Pleckstrin Homology (PH) domain is required for a stable 
recombinant protein fragment. (A) SEC of recombinant proteins equating to the complete (aa 60-
189) or incomplete (aa 93-189) PH domain of TRIOBP-1. The complete domain exists as a single 
clear species, while the incomplete one exists as multiple species, labeled A-C, including one in the 
void volume. (B) CD measurement of the aa 60-189 TRIOBP-1 fragment shows it to be folded and 
principally helical. (C) Western blot of aa 93-189 species from part A, reveals only a breakdown 
product to exist in the soluble fractions, as opposed to the void volume. 
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FIGURE 4: TRIOBP-1 contains two distinct coiled-coil domains, as determined by expression of 
recombinant protein fragments. (A) SEC of recombinant TRIOBP-1 coiled coils, CC, 1-6, aa 281-
652. (B) SDS-PAGE and western blot of the whole lysate from bacteria expressing this fragment, 
nickel affinity purified protein (“input”) and the chromatography fractions indicated in part A, after 
being concentrated. The protein breaks down into distinct fragments. (C) SEC of CC5-6, aa 556-652, 
revealing a single stable protein species. (D) Circular dichroism profile of the major CC5-6 species. 
(E) Recombinant TRIOBP-1 CC4-6, aa 467-652) breaks down prior to nickel affinity purification.  
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FIGURE 5: The central domain of TRIOBP-1 is responsible for its oligomerization. SEC and CD 
measurements of different combinations of the coiled-coils which make up the central domain of 
TRIOBP-1. (A) SEC of aa 281-555. (B) CD of the principle oligomeric state of aa 281-555. (C) SEC 
of aa 281-466. (D) CD of aa 281-466. (E) SEC of aa 281-382. (F) CD of aa 281-382. (G) SEC of aa 
349-466. (H) CD of aa 349-466. 
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FIGURE 6: The oligomeric state of the central domain, analyzed by analytical 
ultracentrifugation. (A) SEC sedimentation velocity data performed on three fragments of the 
TRIOBP-1 central domain, with c(s) fit results shown. (B) Sedimentation profiles (dots) over time for 
the aa 281-382 fragment, 65 µM, experiment in part A, from purple (initial scan) to red (final, scans 
taken at 3 minute intervals), together with the c(s) fit results (lines). Below the graphs, the 
corresponding residuals are shown. (C) Equivalent sedimentation profile for the aa 349-466 fragment, 
55 µM. (D) Equivalent sedimentation profile for the aa 281-466 fragment, 50 µM. (E) Western blot of 
the soluble TRIOBP-1 fragments used for these assays, with polyclonal antibodies raised against 
different parts of the protein used to distinguish them. Note that some degradation of the aa 281-555 
construct can be seem, yielding a fragment corresponding approximately to the aa 281-382 or 324-382 
constructs. This is not seen for the aa 281-466 construct. The left two panels were stained from one 
membrane, and the right two panels from another displaying identical samples. 
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FIGURE 7: The effect of TRIOBP-1 subdomains on actin dynamics. (A) Scheme of the actin assay 
performed. Cell lysate from NLF neuroblastoma cells was separated by ultracentrifugation into F-actin 
and G-actin-containing fractions. The stability of the separated F-actin was assayed by incubating it in 
a depolymerization buffer, and then separating again by ultra-centrifugation into a (stable) F-actin-
containing fraction and a (de-polymerized) G-actin fraction. Similarly, the stability of G-actin was 
assayed by incubating it in polymerization buffer and then separating it into a (stable) G-actin-
containing fraction and a (re-polymerized) G-actin fraction. (B) Western blots of the ensuing fractions, 
showing the abundance of actin and of Flag-tagged TRIOBP-1 fragments which had been transfected 
in. All actin blots are shown under equivalent conditions, as are the top three Flag-blots. The lowest 
Flag blot is shown under a higher gain, due to the much lower level of the aa 556-652 protein after 
transfection (approximately 5-fold lower than aa 281-555). (C) Quantification of the proportion of 
actin in the original F-actin fraction which transferred to the G-actin fraction after incubation under de-
polymerization conditions. (D) Quantification of the proportion of actin in the original G-actin fraction 
which transferred to the F-actin fraction after incubation under polymerization conditions. In both 
graphs n = 3, *: p < 0.05, according to a paired t-test after correction for multiple testing. 
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FIGURE 8: The effect of TRIOBP-1 subdomains on neurite outgrowth. (A) Sample images of 
Neurosreen-1 cells transfected with either an empty vector (“Mock”, n = 171) or one of the following 
TRIOBP-1 fragments: aa 60-189 (“PH”, n = 174), aa 281-555 (“CC1-4”, n = 161) and aa 556-652 
(“CC5-6”, n = 152). Color has been deliberately over-exposed to ensure all neurites are visible. Scale 
bars represent 50 µm. (B) The mean number of neurites per cell (defined as any outgrowth over 20 µm 
in length) shows the PH domain alone to increase neurite number, and the central domain to decrease 
it. *: p < 0.05, **: p < 0.01 after correction for multiple testing. (C) Mean length of the longest neurite 
in each cell. The PH domain has a trend effect, significant before but not after correction for multiple 
testing. All values were compared by one-way ANOVA with Bonferroni correction to the “Mock” 
value. 
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FIGURE 9: Subcellular localization and aggregation propensity of TRIOBP-1 fragments in 
neuroblastoma cells. Flag-tagged TRIOBP-1 protein fragments were transfected into SH-SY5Y cells 
and then visualized using an anti-Flag antibody and immunoflorescence microscopy. F-actin was 
visualized using florescent-labeled phalloidin. For each construct, the amino acid, aa, position in full 
length TRIOBP-1 is displayed. All scale bars represent 20 µm. (A) The full length protein, aa 1-652, 
which aggregates. (B) The N-terminal region, aa 1-280. (C) The PH domain, aa 60-189. (D) CC1-6, aa 
281-652, which forms aggregates. (E) CC1-4, aa 281-555, which forms aggregates. (F) CC5-6, aa 556-
652. (G) CC5, aa 556-619. 
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FIGURE 10: Further subcellular localization and aggregation propensity of TRIOBP-1 
fragments in neuroblastoma cells. Flag-tagged TRIOBP-1 protein fragments were transfected into 
SH-SY5Y cells and then visualized using an anti-Flag antibody and immunofluorescence microscopy. 
F-actin was visualized using florescent-labeled phalloidin. For each construct, the amino acid, aa, 
position in full length TRIOBP-1 is displayed. All scale bars represent 20 µm. (A) CC3-6 of TRIOBP-
1, encoded by aa 383-652. (B) CC3-4, aa 383-555. (C) CC1-2, aa 281-382, however for this image an 
ECFP-fused construct was used and so anti-TRIOBP-1 antibody is used alongside the ECFP 
florescence to visualize the protein. (D) The full length protein, aa 1-652, with a ECFP fusion protein. 
Note, that while ECFP stains the whole aggregate, an anti-TRIOBP-1 antibody stains only the 
periphery. This is consistent with previous reports of TRIOBP-1 aggregates (28) and likely represents 
the antibody being unable to penetrate the core of the densely packed protein aggregate. (E) CC2-4, 
including the 25 aa linker between CC1 & CC2, aa 324-652, which forms aggregates. (F) CC2-4, 
excluding the 25 aa linker between CC1 & CC2, aa 349-652. 
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FIGURE 11: Confirmation of an aggregation-critical region between coiled-coils 1 and 2 of 
TRIOBP-1. (A) Cell lysates and corresponding purified insoluble protein pellets of SH-SY5Y cells 
expressing Flag-tagged TRIOBP-1 aa 324-652 or 349-652. (B) In a blinded experiment, cells were 
transfected with TRIOBP-1 fragments and the mean number of aggregates per cell was quantified. 
Standard errors of the mean are shown, along with p-values determined by one-way ANOVA, with 
Bonferroni correction for multiple testing. Constructs used encoded TRIOBP-1 aa 190-652 (n = 65), 
aa 281-652 (n = 71), aa 324-652 (n = 72), aa 349-652 (n = 71) or aa 383-652 (n = 65). Over the whole 
dataset, p < 0.001. ns: not significant; *: p < 0.05, ***: p < 0.001. (C) In the same experiment, the 
mean diameter of Flag-positive aggregates did not vary significantly between constructs. (D) Western 
blot of lysates from SH-SY5Y cells transfected with the TRIOBP-1 constructs used in the blinded 
aggregation assay. (E) Flag-tagged TRIOBP-1 protein fragment aa 190-652 transfected into SH-SY5Y 
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cells. (F) Transfection of an identical construct lacking the aggregation critical region aa 324-348. (G) 
Transfection of a construct encoding TRIOBP-1 aa 1-382. All scale bars represent 20 μm. 
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FIGURE 12: Summary of the domain structure of TRIOBP-1. (A) The Pleckstrin Homology (PH, 
purple) domain and coiled coil regions of TRIOBP-1 are shown. Coiled coils are divided between 
those which constitute the central domain (CC1-CC3 and possibly CC4, red) and the C-terminal 
domain (CC5-CC6). Regions of interest are indicated in green, including the aggregation critical 
region and the oligomeric states of selected fragments of TRIOBP-1 when expressed as recombinant 
proteins. (B) Sequence of the 25 amino acid region found to be essential for aggregation. It is rich in 
prolines (shown in purple) and charged residues (red for positive charge, blue for negative). 
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  PH domain Central domain C-terminal domain 
Location on TRIOBP-1       
Amino acids 60-189 281-555 556-652 
Coiled-coils N/A 1-4 5-6 
Actin assay       
Segregates with F-actin No Yes Yes 
Segregates with G-actin Yes Yes Yes 
Effect on F-actin de-polymerization No effect Inhibition Trend inhibition 
Effect on G-actin polymerization No effect No effect Trend promotion 
Neurite assay       
Effect on neurite number Increase Decrease No effect 
Effect on longest neurite length Trend increase No effect No effect 
 
TABLE 1: Summary of functional assays performed on isolated domains of TRIOBP-1. Based on 
data found in figures 7 and 8. 
